• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

联合脑脊液和 PI-2620 tau-PET 进行基于生物标志物的阿尔茨海默病和 4R-tau 病的分层。

Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.

机构信息

Neuroscience, Monash University, Melbourne, Australia.

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, München, Germany.

出版信息

Alzheimers Dement. 2024 Oct;20(10):6896-6909. doi: 10.1002/alz.14185. Epub 2024 Sep 12.

DOI:10.1002/alz.14185
PMID:39263969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485081/
Abstract

INTRODUCTION

Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel biomarker-based algorithm to characterize AD and 4RTs.

METHODS

We cross-sectionally assessed combinations of cerebrospinal fluid measures (CSF p-tau and t-tau) and F-PI-2620 tau-positron emission tomography (PET) in patients with AD (n = 64), clinically suspected 4RTs (progressive supranuclear palsy or corticobasal syndrome, n = 82) and healthy controls (n = 19).

RESULTS

Elevated CSF p-tau and cortical F-PI-2620 binding was characteristic for AD while normal CSF p-tau with elevated subcortical F-PI-2620 binding was characteristic for 4RTs. F-PI-2620-assessed posterior cortical hypoperfusion could be used as an additional neuronal injury biomarker in AD.

DISCUSSION

The specific combination of CSF markers and F-PI-2620 tau-PET in disease-specific regions facilitates the biomarker-guided stratification of AD and 4RTs. This has implications for biomarker-aided diagnostic workflows and the advancement in clinical trials.

HIGHLIGHTS

Novel biomarker-based algorithm for differentiating AD and 4R-tauopathies. A combination of CSF p-tau and F-PI-2620 discriminates AD versus 4R tauopathies. Hypoperfusion serves as an additional neuronal injury biomarker in AD.

摘要

简介

生物标志物研究的最新进展提高了阿尔茨海默病（AD）的诊断和监测水平，但目前缺乏基于体内生物标志物的评估 4R-tau 病（4RT）患者的方法。我们提出了一种新的基于生物标志物的算法来描述 AD 和 4RTs。

方法

我们在 AD 患者（n=64）、临床疑似 4RTs（进行性核上性麻痹或皮质基底节综合征，n=82）和健康对照者（n=19）中，进行了脑脊液指标（CSF p-tau 和 t-tau）和 F-PI-2620 tau-PET 的联合检测。

结果

升高的 CSF p-tau 和皮质 F-PI-2620 结合是 AD 的特征，而正常 CSF p-tau 与升高的皮质下 F-PI-2620 结合是 4RTs 的特征。F-PI-2620 评估的后部皮质低灌注可作为 AD 的另一个神经元损伤生物标志物。

讨论

特定疾病区域的 CSF 标志物和 F-PI-2620 tau-PET 的特定组合有助于 AD 和 4RTs 的生物标志物指导分层。这对生物标志物辅助诊断工作流程和临床试验的进展具有重要意义。

重点

用于区分 AD 和 4R-tau 病的新型基于生物标志物的算法。CSF p-tau 和 F-PI-2620 的组合可区分 AD 与 4R tau 病。低灌注可作为 AD 的另一个神经元损伤生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/8a89bb63ad05/ALZ-20-6896-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/f5deb3600d4e/ALZ-20-6896-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/da6651e2d0c1/ALZ-20-6896-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/9f94bc62bc73/ALZ-20-6896-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/ea8754ad1955/ALZ-20-6896-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/8a89bb63ad05/ALZ-20-6896-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/f5deb3600d4e/ALZ-20-6896-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/da6651e2d0c1/ALZ-20-6896-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/9f94bc62bc73/ALZ-20-6896-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/ea8754ad1955/ALZ-20-6896-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/623c/11485081/8a89bb63ad05/ALZ-20-6896-g001.jpg

相似文献

1
Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.联合脑脊液和 PI-2620 tau-PET 进行基于生物标志物的阿尔茨海默病和 4R-tau 病的分层。
Alzheimers Dement. 2024 Oct;20(10):6896-6909. doi: 10.1002/alz.14185. Epub 2024 Sep 12.
2
Additive value of [F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome.[F]PI-2620 灌注成象在进行性核上性麻痹和皮质基底节综合征中的附加价值。
Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):423-434. doi: 10.1007/s00259-022-05964-w. Epub 2022 Sep 14.
3
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.MAPT R406W 增加了 Tau T217 的磷酸化，而不伴有淀粉样蛋白病理。
Ann Clin Transl Neurol. 2021 Sep;8(9):1817-1830. doi: 10.1002/acn3.51435. Epub 2021 Aug 2.
4
Subcortical tau is linked to hypoperfusion in connected cortical regions in 4-repeat tauopathies.皮质下 tau 与 4 重复 tau 病中连接皮质区域的低灌注有关。
Brain. 2024 Jul 5;147(7):2428-2439. doi: 10.1093/brain/awae174.
5
Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.两种常见tau蛋白病（阿尔茨海默病和进行性核上性麻痹）中脑脊液tau蛋白的不同改变
J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):244-50. doi: 10.1136/jnnp-2014-308004. Epub 2014 Jun 4.
6
Binding characteristics of [F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET.[F]PI-2620 的结合特性通过 PET 区分了不同 tau 病中的临床预测 tau 同工型。
J Cereb Blood Flow Metab. 2021 Nov;41(11):2957-2972. doi: 10.1177/0271678X211018904. Epub 2021 May 27.
7
A Machine Learning-Based Approach to Discrimination of Tauopathies Using [ F]PM-PBB3 PET Images.基于机器学习的 [ F]PM-PBB3 PET 图像对 Tau 病的鉴别方法。
Mov Disord. 2022 Nov;37(11):2236-2246. doi: 10.1002/mds.29173. Epub 2022 Aug 28.
8
Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [F]PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies.分子模拟揭示了[F]PI-2620对来自3R/4R Tau病和4R Tau病的Tau细丝的不同能量和动力学结合特性。
ACS Chem Neurosci. 2022 Jul 20;13(14):2222-2234. doi: 10.1021/acschemneuro.2c00291. Epub 2022 Jun 28.
9
SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease.SCRN1：与阿尔茨海默病中的 tau 相关的脑脊液生物标志物。
Alzheimers Dement. 2023 Oct;19(10):4609-4618. doi: 10.1002/alz.13042. Epub 2023 Mar 22.
10
F-Florzolotau Positron Emission Tomography Imaging of Tau Pathology in the Living Brains of Patients with Corticobasal Syndrome.F-Florzolotau 正电子发射断层扫描对皮质基底节综合征患者活体大脑 Tau 病理学的成像研究。
Mov Disord. 2023 Apr;38(4):579-588. doi: 10.1002/mds.29338. Epub 2023 Feb 7.

引用本文的文献

1
Comorbid pathologies and their impact on progressive supranuclear palsy: current view.共病病理及其对进行性核上性麻痹的影响：当前观点
J Neural Transm (Vienna). 2025 Aug 12. doi: 10.1007/s00702-025-03005-y.
2
Developing a novel reference region for [F]PI-2620-PET imaging to facilitate the assessment of 4-repeat tauopathies.开发用于[F]PI-2620-PET成像的新型参考区域，以促进对4重复tau蛋白病的评估。
Eur J Nucl Med Mol Imaging. 2025 Jun 10. doi: 10.1007/s00259-025-07396-8.
3
Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference.

本文引用的文献

1
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.CSF MTBR-tau243 是阿尔茨海默病中 tau 缠结病理的特异性生物标志物。
Nat Med. 2023 Aug;29(8):1954-1963. doi: 10.1038/s41591-023-02443-z. Epub 2023 Jul 13.
2
A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases.一种统一的分类方法，对神经疾病中的蛋白质生物标志物的临床效用进行评分。
EBioMedicine. 2023 Mar;89:104456. doi: 10.1016/j.ebiom.2023.104456. Epub 2023 Feb 4.
3
Assessment of perfusion deficit with early phases of [F]PI-2620 tau-PET versus [F]flutemetamol-amyloid-PET recordings.
tau蛋白病的病理生理学、生物标志物及治疗方法洞察：2024年tau蛋白病全球会议论文集
Alzheimers Dement. 2025 May;21(5):e70078. doi: 10.1002/alz.70078.
4
Differentiating Progressive Supranuclear Palsy and Corticobasal Syndrome: Insights from Cerebrospinal Fluid Biomarkers-A Narrative Review.鉴别进行性核上性麻痹和皮质基底节综合征：脑脊液生物标志物的见解——一篇叙述性综述
Medicina (Kaunas). 2025 Apr 11;61(4):701. doi: 10.3390/medicina61040701.
5
Exploring the origins of frequent tau-PET signal in vermal and adjacent regions.探索蚓部及相邻区域tau正电子发射断层扫描（PET）信号频繁出现的起源。
Eur J Nucl Med Mol Imaging. 2025 Mar 18. doi: 10.1007/s00259-025-07199-x.
6
Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials.用于临床试验的进行性核上性麻痹疾病进展生物标志物。
Brain Commun. 2025 Jan 16;7(1):fcaf022. doi: 10.1093/braincomms/fcaf022. eCollection 2025.
7
Early-phase F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer's disease: a comparison with F-FDG-PET and early-phase amyloid-PET.早期F-氟代托品 tau正电子发射断层扫描作为阿尔茨海默病脑代谢的替代指标：与F-氟代脱氧葡萄糖正电子发射断层扫描及早期淀粉样蛋白正电子发射断层扫描的比较
Eur J Nucl Med Mol Imaging. 2025 May;52(6):1958-1969. doi: 10.1007/s00259-024-07063-4. Epub 2025 Jan 24.
8
Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.用于神经退行性疾病中tau蛋白和α-突触核蛋白成像的正电子发射断层扫描（PET）示踪剂开发策略。
RSC Med Chem. 2024 Nov 20. doi: 10.1039/d4md00576g.
评估[F]PI-2620 tau-PET 早期相与[F]flutemetamol-淀粉样蛋白-PET 记录的灌注不足。
Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1384-1394. doi: 10.1007/s00259-022-06087-y. Epub 2022 Dec 27.
4
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.血浆 p-tau181、NfL 和 GFAP 在现患神经退行性痴呆临床队列中的诊断价值。
Alzheimers Res Ther. 2022 Oct 12;14(1):153. doi: 10.1186/s13195-022-01093-6.
5
Additive value of [F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome.[F]PI-2620 灌注成象在进行性核上性麻痹和皮质基底节综合征中的附加价值。
Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):423-434. doi: 10.1007/s00259-022-05964-w. Epub 2022 Sep 14.
6
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.磷酸化tau 结合亚阈值 tau-PET 可预测淀粉样蛋白阳性个体 tau 积聚率的增加。
Brain. 2023 Apr 19;146(4):1580-1591. doi: 10.1093/brain/awac329.
7
Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [F]PI-2620 PET/MRI study.进行性核上性麻痹中tau与功能网络连接的相互作用：一项[F]PI-2620 PET/MRI研究。
Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):103-114. doi: 10.1007/s00259-022-05952-0. Epub 2022 Sep 1.
8
Evaluation of tau deposition using F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study.使用 F-PI-2620 PET 评估 MCI 和早期 AD 患者中的 tau 沉积——一项 MissionAD tau 子研究。
Alzheimers Res Ther. 2022 Jul 27;14(1):105. doi: 10.1186/s13195-022-01048-x.
9
Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [F]PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies.分子模拟揭示了[F]PI-2620对来自3R/4R Tau病和4R Tau病的Tau细丝的不同能量和动力学结合特性。
ACS Chem Neurosci. 2022 Jul 20;13(14):2222-2234. doi: 10.1021/acschemneuro.2c00291. Epub 2022 Jun 28.
10
Tau deposition patterns are associated with functional connectivity in primary tauopathies.tau 沉积模式与原发性 tau 病的功能连接相关。
Nat Commun. 2022 Mar 15;13(1):1362. doi: 10.1038/s41467-022-28896-3.